Moneycontrol PRO
Upcoming Webinar:Innovate Your Future at India Inc. on the Move on August 26 and 27, 2021 at 10am, with Rockwell Automation
you are here: HomeNewsTrendsHealth

COVID-19 vaccines for children | AIIMS Delhi to start recruitment for Covaxin clinical trials for 6-12 age group from June 15

The report further said that the clinical trial of children of 2-6 age group will start after that.

June 14, 2021 / 04:19 PM IST
For asymptomatic novel coronavirus infection among children, the guidelines recommended no specific medication and promoted COVID-appropriate behaviour. (Representative Image)

For asymptomatic novel coronavirus infection among children, the guidelines recommended no specific medication and promoted COVID-appropriate behaviour. (Representative Image)


All India Institute of Medical Sciences (AIIMS) Delhi to start recruitment for clinical trials from June 15 onwards for the children who are in the age group of 6-12 years, news agency ANI has reported.

The report further said that the clinical trial of children of 2-6 age group will start after that.

AIIMS Delhi has completed the clinical trial for a single dose of Covaxin for the 12-18 age group, it said.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The screening of children for trial of Covaxin, India's first indigenously developed COVID-19 vaccine among those aged between 2 and 18 had started at AIIMS Delhi on June 7.

As per an Indian Express report, the Centre is targeting to cover 80 percent of the 130 million people falling in the 12-18 age group as part of the COVID-19 vaccination drive for children. Thus, the government would need to procure around 210 million shots of a two-dose COVID-19 vaccine.

Follow our LIVE blog for latest updates of the novel coronavirus pandemic

While Pfizer-BioNTech’s jab has been approved in the European Union for use in the 12-15 age bracket, the news report suggests that Covaxin, the COVID-19 vaccine developed by Bharat Biotech, would be used in India for this purpose.

The Drugs Controller General of India (DCGI) had granted permission to Bharat Biotech for conducting trials of its COVID-19 vaccine on children. The DCGI's approval came after a recommendation by a Subject Expert Committee (SEC) on May 12.

Recently, AIIMS Patna too started a similar trial for Bharat Biotech's coronavirus vaccine on children aged between 12 and 18.

The trial will take place in 525 subjects at various sites, including AIIMS Delhi, AIIMS Patna and Meditrina Institute of Medical Sciences, Nagpur.

Meanwhile, a plea has been moved in the Delhi High Court seeking a stay on phase II/III clinical trials of Covaxin on the 2-18 age group.

The application was moved in a petition filed in May for setting aside the permission granted by the DCGI to Bharat Biotech for conducting trials of its vaccine on children.

The petitioner, Sanjeev Kumar, had raised an apprehension that the children who would be part of the trial could suffer adverse health or mental effects due to the testing of the vaccine on them.

He has claimed in his application that while the issue was pending before the high court with notices issued to the Centre and Bharat Biotech, the trials have commenced from June.

Kumar has contended that on July 15, the next date of hearing of the petition, the government and the company would say that the trials have commenced and thus, the plea challenging the permission granted by DCGI would become infructuous.

Meanwhile, Centre plans to vaccinate all adults by the end of this year.

Follow our full coverage of the coronavirus pandemic here.

Moneycontrol News
first published: Jun 14, 2021 04:17 pm

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark